CN116973473A - Related substance detection method of felodipine - Google Patents
Related substance detection method of felodipine Download PDFInfo
- Publication number
- CN116973473A CN116973473A CN202310778806.2A CN202310778806A CN116973473A CN 116973473 A CN116973473 A CN 116973473A CN 202310778806 A CN202310778806 A CN 202310778806A CN 116973473 A CN116973473 A CN 116973473A
- Authority
- CN
- China
- Prior art keywords
- mobile phase
- felodipine
- solution
- phosphate buffer
- impurity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 title claims abstract description 49
- 229960003580 felodipine Drugs 0.000 title claims abstract description 49
- 239000000126 substance Substances 0.000 title claims abstract description 28
- 238000001514 detection method Methods 0.000 title claims description 28
- 238000000034 method Methods 0.000 claims abstract description 27
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000010828 elution Methods 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 7
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 6
- 239000012535 impurity Substances 0.000 claims description 53
- 239000012071 phase Substances 0.000 claims description 41
- 239000000243 solution Substances 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 239000008055 phosphate buffer solution Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 abstract description 9
- 239000007864 aqueous solution Substances 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 238000011208 chromatographic data Methods 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000012490 blank solution Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000007939 sustained release tablet Substances 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 2
- NAYRZLVSOLIQSH-UHFFFAOYSA-N acetonitrile;methanol;phosphoric acid Chemical compound OC.CC#N.OP(O)(O)=O NAYRZLVSOLIQSH-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010829 isocratic elution Methods 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
- G01N30/8624—Detection of slopes or peaks; baseline correction
- G01N30/8631—Peaks
- G01N30/8634—Peak quality criteria
Abstract
The application relates to a method for detecting related substances of felodipine, which adopts high performance liquid chromatography. The application adopts octadecylsilane chemically bonded silica as chromatographic column filler, and takes the mixed solution of acid aqueous solution and organic solvent as mobile phase for gradient elution, and has the characteristics of simplicity, specificity, accuracy and high sensitivity. The application solves the problems of separation and measurement of related substances in felodipine, and provides technical guarantee for ensuring the quality of felodipine and the safety of subsequent medicines.
Description
Technical Field
The application belongs to the field of chemical analysis, and particularly relates to a method for detecting related substances of felodipine.
Background
The related substances are raw materials, intermediates, side reaction products, degradation impurities and the like which are brought in the drug synthesis production process, and the quality and the safety of the drug can be controlled by detecting the related substances.
Felodipine, chemical name (±) -2, 6-dimethyl-4- (2, 3-dichlorophenyl) -1, 4-dihydro-3, 5-pyridine-dicarboxylic acid methyl ester ethyl ester. Felodipine is a medicine for treating cardiovascular system, and is mainly used for treating hypertension and stable angina pectoris.
Felodipine and related substances have the structural formulas shown in the following table:
。
the impurity A, B, C, D, E, F of felodipine and the intermediate 1 are process impurities, which affect the purity of the medicine and relate to the effectiveness and safety of the medicine. The esterified substance impurity E is a byproduct generated by the reaction in the dehydration cyclization step when felodipine is synthesized, cannot be completely removed through a refining process, and has important significance on the quality and safety of raw materials and preparations because the limit of the impurity E in felodipine raw materials is controlled below 0.10 percent based on the chemical impurity control requirement and related guiding principles. The detection of the impurity E of felodipine is not reported, and the detection methods of felodipine in the United states pharmacopoeia, british pharmacopoeia and Chinese pharmacopoeia in the existing standards cannot effectively separate the impurity C and the impurity E, and influence the impurity quantification. Therefore, the detection method of the felodipine related substances is significant.
Disclosure of Invention
The application aims to provide a high performance liquid chromatography detection method for felodipine related substances, which can effectively determine the content of felodipine and related substances thereof, has the characteristics of simplicity, specificity, accuracy and high sensitivity, and is suitable for detecting related substances in felodipine.
In order to achieve the above object, the present application is realized by the following technical scheme:
the method for detecting the impurity E in felodipine adopts a high performance liquid chromatography, and the chromatographic conditions are as follows: the chromatographic column uses octadecylsilane chemically bonded silica as filler, and the mobile phase is a mixed solvent of organic phase and water phase, and gradient elution is carried out.
Further, the aqueous phase is phosphate buffer solution, the pH is 2.8-3.2, and the pH is preferably 3.0.
Further, the mobile phase is divided into a mobile phase A and a mobile phase B, acetonitrile-phosphate buffer-methanol (25:50:25) is used as the mobile phase A, and phosphate buffer-methanol (25:75) is used as the mobile phase B.
Further, the gradient elution procedure was:
。
further, the method can also detect one or more related substances in the impurities A-D, the impurity F and the intermediate 1 at the same time.
Further, the column is preferably a column with octadecylsilane chemically bonded silica as a filler, 4.6mm×150mm,5 μm or equivalent in performance.
Further, the chromatographic conditions also include a detection wavelength of 220 to 260nm, preferably 230 to 240nm.
Further, the chromatographic conditions also include a flow rate of the mobile phase, which is 1.0.+ -. 0.2ml/min.
Further, the chromatographic conditions further include a chromatographic column temperature of 30 ℃ ± 5 ℃.
Further, the chromatographic conditions further comprise a sample injection volume, wherein the sample injection volume is 20-100 mu l, and preferably 40-80 mu l.
Further, the gradient elution procedure is preferably:
。
the beneficial effects of the application are as follows:
1. the high-efficiency liquid phase detection method can effectively separate the impurity E and other impurities;
2. the detection method can detect the impurities A-F and the intermediate 1 in felodipine simultaneously, and has the characteristics of simplicity, specificity, accuracy and high sensitivity;
3. the method is not only suitable for detecting related substances of felodipine bulk drugs, but also suitable for detecting related substances of solid preparations such as sustained release tablets, and the detection method is not interfered by common auxiliary materials;
4. the application screens out the optimal chromatographic analysis condition and solution preparation method through a large number of experiments. Experimental results show that the felodipine related substance high-performance liquid chromatography analysis method provided by the application has the advantages of high separation degree and good stability, can effectively separate related substances and accurately detect the content of the related substances, is beneficial to objectively, accurately and comprehensively evaluating the quality of felodipine, provides technical guarantees for ensuring the quality of felodipine and the safety of subsequent medicines, and has important practical significance for controlling the quality of products.
Drawings
FIG. 1 is a chromatogram of a blank solution of example 1.
FIG. 2 is a chromatogram of a solution suitable for use in the system of example 1.
FIG. 3 is a chromatogram of the sample solution of example 1.
FIG. 4 is a chromatogram of a solution suitable for use in the system of example 2.
FIG. 5 is a chromatogram of a solution for the applicability of the system of example 3.
FIG. 6 is a chromatogram of a blank solution of example 4.
FIG. 7 is a chromatogram of a solution for the applicability of the system of example 4.
FIG. 8 is a chromatogram of the sample solution of example 4.
FIG. 9 is a chromatogram of comparative example 1 system applicability solution.
FIG. 10 is a chromatogram of comparative example 2 system applicability solution.
FIG. 11 is a chromatogram of comparative example 3 system applicability solution.
Fig. 12 is a linear relationship diagram of the impurity E.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more apparent, the present application will be further described in detail by the following examples, which are only for explaining the present application and do not represent the scope of the present application defined by the claims.
The reagents and raw materials used in the application are all commercially available.
Example 1
1. Solution preparation
Phosphate buffer: taking 0.05mol/L sodium dihydrogen phosphate aqueous solution, and regulating the pH value to 3.0+/-0.05 by using phosphoric acid.
Mobile phase: acetonitrile-phosphate buffer-methanol (25:50:25) was used as mobile phase A, and phosphate buffer-methanol (25:75) was used as mobile phase B.
Blank solvent: mobile phase a.
System applicability solution: and (3) taking proper amounts of felodipine reference substances, impurities A, B, C, D, E, F and intermediate 1 reference substances, precisely weighing, adding the mobile phase A for dissolving and diluting to prepare a solution containing about 0.3mg of felodipine per 1ml, wherein the impurities B and C are about 1.5 mug respectively, and the other impurities are about 0.3 mug respectively.
Test solution: the product is taken to be proper, and mobile phase A is added for dissolution and dilution to prepare a solution containing about 0.3mg per 1 ml.
2. Chromatographic conditions
Chromatographic column: octadecylsilane chemically bonded silica is used as a filler, 4.6mm is 150mm, and 5 mu m is adopted;
flow rate: 1.0ml/min;
column temperature: 30 ℃;
detection wavelength: 238nm;
sample injection volume: 40 μl;
the elution procedure was as follows:
。
3. measurement method
And precisely measuring the blank solvent, the system applicability solution and the sample solution respectively, injecting the blank solvent, the system applicability solution and the sample solution into a liquid chromatograph, and recording a chromatogram.
The chromatographic data are shown in the following table:
。
under the chromatographic conditions, the blank solution (i.e., mobile phase a) had no interference with the detection; the separation degree of each impurity in the system applicability solution is good, and the collection time is proper; the impurities in the felodipine crude drug test solution can be effectively separated and quantified.
Example 2
The solution formulation was the same as in example 1.
The chromatographic conditions differ from example 1 only in that the phosphate buffer pH in the mobile phase is 2.8.
And (5) injecting the system applicability solution into a liquid chromatograph, and recording a chromatogram.
The chromatographic data are as follows:
。
example 3
The solution formulation was the same as in example 1.
The chromatographic conditions differ from example 1 only in that the phosphate buffer pH in the mobile phase is 3.2.
And (5) injecting the system applicability solution into a liquid chromatograph, and recording a chromatogram.
The chromatographic data are as follows:
。
example 4
1. Solution preparation
Phosphate buffer: 0.05mol/L sodium dihydrogen phosphate aqueous solution is taken and the pH value is regulated to 3.0 by phosphoric acid.
Mobile phase: acetonitrile-phosphate buffer-methanol (25:50:25) was used as mobile phase A, and phosphate buffer-methanol (25:75) was used as mobile phase B.
System applicability solution: taking a proper amount of the reference substances of the impurity A, the impurity B, the impurity C and the felodipine, adding the mobile phase A for dissolving and diluting to prepare solutions containing about 0.15mg of felodipine, 3 mug of the impurity A and 0.75 mug of the impurity B and the impurity C in each 1 ml.
Test solution: the felodipine sustained release tablet (not less than 20 tablets) is precisely weighed, ground, a proper amount of fine powder (30 mg equivalent to felodipine) is put into a 200ml measuring flask, 50ml of acetonitrile, 50ml of methanol and ultrasound are added for 15 minutes, 60ml of phosphate buffer solution (pH 3.0) is added, the mixture is shaken for 30 minutes, and the mixture is diluted to a scale by the phosphate buffer solution (pH 3.0). An appropriate amount was collected, centrifuged at 4000 rpm for 15 minutes, the supernatant was collected, filtered, and 4ml of the primary filtrate was discarded, followed by collection.
Blank solvent is mobile phase a.
2. Chromatographic conditions
Chromatographic column: octadecylsilane chemically bonded silica as packing material (ZORBAX Eclipse XDB-C18, 150X4.6 mm,5 μm or column with equivalent performance);
flow rate: 1.0ml/min;
column temperature: 30 ℃;
detection wavelength: 254nm;
sample injection volume: 80 μl;
the elution procedure was as follows:
。
3. measurement method
And precisely measuring the blank solution, the system applicability solution and the sample solution respectively, injecting the blank solution, the system applicability solution and the sample solution into a liquid chromatograph, and recording a chromatogram.
The chromatographic data are shown in the following table:
。
according to the figures 1-8 and the chromatographic data, the detection method provided by the application is used for detecting related substances of felodipine bulk drug and felodipine sustained release tablets, and felodipine can be effectively separated from adjacent impurities and impurities. The blank solution had no effect on the detection. The preparation auxiliary material has no interference to detection of related substances, and the method is not only suitable for detection of crude drugs, but also suitable for detection of preparations.
The result shows that under the chromatographic condition, the separation degree of the felodipine peak and the impurity peak meets the requirement, and the felodipine and various impurities can be accurately quantified.
Comparative example 1
A method for detecting related substances of felodipine, wherein the solution preparation method is the same as in example 1. The chromatographic conditions were different from those of example 1 only in the mobile phase and elution procedure, and the other conditions were the same. Specifically, 6.9g of sodium dihydrogen phosphate monohydrate is taken and dissolved in 400ml of water, 8ml of 1mol/L phosphoric acid solution is added, water is added for dilution to 1L, phosphate buffer solution is prepared, and methanol-acetonitrile-phosphate buffer solution (40:20:40) is used; isocratic elution.
And (5) injecting the system applicability solution into a liquid chromatograph, and recording a chromatogram. The measurement method and calculation method were the same as in example 1.
The chromatographic data are as follows:
。
under the chromatographic condition, sampling the solution with the system applicability, and separating the impurity E from the impurity C, wherein the separation effect is not ideal, and the separation cannot be realized.
Comparative example 2
A method for detecting related substances of felodipine, wherein the solution preparation method is the same as in example 1. The chromatographic conditions were different from those of example 1 only in the mobile phase and elution procedure, and the other conditions were the same. Specifically, 6.9g of sodium dihydrogen phosphate monohydrate is taken and dissolved in 400ml of water, 8ml of 1mol/L phosphoric acid solution is added, water is added for dilution to 1L, phosphate buffer solution is prepared, and methanol-acetonitrile-phosphate buffer solution (50:18:32) is taken as a mobile phase; isocratic elution.
And (5) injecting the system applicability solution into a liquid chromatograph, and recording a chromatogram.
The measurement method and calculation method were the same as in example 1.
The chromatographic data are as follows:
。
under the chromatographic condition, sampling the solution with the system applicability, wherein the impurity A, B has poor separation degree, the separation effect of the impurity E and the impurity C is still not ideal, and the separation cannot be realized.
Comparative example 3
Compared to example 1, the only differences are the mobile phase and the elution gradient:
(1) Methanol is used as a mobile phase A, acetonitrile is used as a mobile phase B, and phosphate buffer is used as a mobile phase C;
(2) Elution was performed according to the following gradient:
。
and (5) injecting the system applicability solution into a liquid chromatograph, and recording a chromatogram.
The chromatographic data are as follows:
。
by adopting the chromatographic condition detection, compared with the example 1, each impurity can be separated, but the main peak of felodipine and the peak time of each impurity are late, the detection time is prolonged, and the experimental efficiency is low.
In order to further illustrate the beneficial effects of the present application, the present application provides the following test examples.
Test examples
The method experiments are carried out on the impurities A-F and the intermediate 1, and the results show that the peak area and the concentration of each impurity of felodipine in the concentration range are in a linear relation, and the correlation coefficient R 2 All are larger than 0.990, and the method has wide linear range and high accuracy. Impurity E is an important impurity in felodipine impurity mass spectra, and is represented by impurity E, exhibiting partial linearity, quasi-linearityData of the certainty test.
1. Linearity test
Linear solution preparation: and (3) taking a proper amount of felodipine impurity E reference substance, preparing a reference substance stock solution with a certain concentration, and diluting the reference substance stock solution into 6 parts of linear solutions with different concentrations.
Chromatographic conditions were the same as in example 1.
。
2. Accuracy test
Accuracy solution preparation: about 15mg of felodipine crude drug is taken, 9 parts of felodipine impurity E reference substance solutions (divided into 3 parts of low concentration, medium concentration and high concentration) with different volumes and a mobile phase A are respectively added into the felodipine crude drug, and the felodipine impurity E reference substance solutions are diluted to the scale.
Chromatographic conditions were tested in a simultaneous linear fashion.
。
The result shows that the method has good recovery rate of the impurity E, and the impurity E can be effectively detected.
The foregoing is a further detailed description of the application in connection with specific embodiments, and it is not intended that the application be limited to such description. It will be apparent to those skilled in the art that several simple deductions or substitutions may be made without departing from the spirit of the application, and these should be considered to be within the scope of the application.
Claims (8)
1. A method for detecting an impurity E in felodipine, wherein the impurity E has the following structure:
；
the method adopts high performance liquid chromatography, and the chromatographic conditions are as follows: the chromatographic column uses octadecylsilane chemically bonded silica as filler, and the mobile phase is a mixed solvent of organic phase and water phase, and gradient elution is carried out.
2. The method according to claim 1, wherein the aqueous phase is phosphate buffer with a pH of 2.8-3.2.
3. The detection method according to claim 1, wherein the mobile phase is divided into mobile phase A and mobile phase B, acetonitrile-phosphate buffer-methanol (25:50:25) is used as mobile phase A, phosphate buffer-methanol (25:75) is used as mobile phase B,
the gradient elution procedure was:
。
4. the method according to claim 1, wherein the method is further capable of detecting one or more of the following impurities a to D, impurity F, intermediate 1 simultaneously, having the following structural formula:
。
5. the detection method according to claim 1 to 4, wherein the chromatographic conditions of the high performance liquid chromatography further include one or more of the following i to iv:
i, the detection wavelength is 220-260 nm;
II, the flow rate of the mobile phase is 1.0+/-0.2 ml/min;
III, the temperature of the chromatographic column is 30+/-5 ℃;
IV, sampling volume is 20-100 mu l.
6. The detection method according to claim 1 to 4, wherein the chromatographic conditions of the high performance liquid chromatography further include one or more of the following i to iv:
i, the detection wavelength is 230-240 nm;
II, the flow rate of the mobile phase is 1.0+/-0.2 ml/min;
III, the temperature of the chromatographic column is 30+/-5 ℃;
IV, sampling volume is 40-80 mu l.
7. The detection method of claim 1-4, wherein the detection method is applied to detection of related substances of felodipine bulk drugs and preparations.
8. The method for detecting related substances of felodipine is characterized by comprising impurities A-F and an intermediate 1, and comprises the following steps:
injecting the solution to be detected into a liquid chromatograph, and taking acetonitrile-phosphate buffer solution-methanol (25:50:25) as a mobile phase A; taking phosphate buffer solution-methanol (25:75) as a mobile phase B, performing gradient elution, and recording a chromatogram;
the pH of the phosphate buffer solution is 3.0;
column chromatography column with octadecylsilane chemically bonded silica as filler, 4.6mm×150mm,5 μm;
the flow rate is 1.0ml/min, and the column temperature is 30 ℃;
the gradient elution procedure was:
。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310778806.2A CN116973473A (en) | 2023-06-29 | 2023-06-29 | Related substance detection method of felodipine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310778806.2A CN116973473A (en) | 2023-06-29 | 2023-06-29 | Related substance detection method of felodipine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116973473A true CN116973473A (en) | 2023-10-31 |
Family
ID=88474030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310778806.2A Pending CN116973473A (en) | 2023-06-29 | 2023-06-29 | Related substance detection method of felodipine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116973473A (en) |
-
2023
- 2023-06-29 CN CN202310778806.2A patent/CN116973473A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111239299B (en) | Method for separating and measuring palbociclib and impurities thereof | |
| CN106706769B (en) | Separation and determination method of empagliflozin and optical isomer thereof | |
| CN107525877B (en) | Method for separating and determining brexpiprazole and impurities thereof by adopting liquid chromatography | |
| CN116973473A (en) | Related substance detection method of felodipine | |
| CN114295748B (en) | Method for detecting pitavastatin calcium intermediate and impurities | |
| CN114324636B (en) | Method for measuring vitamin B6 and related impurities thereof by HPLC (high Performance liquid chromatography) | |
| CN110606846A (en) | Tofacitinib citrate impurity and analysis method and application thereof | |
| CN109738536B (en) | Method for separating benzaldehyde and nitrobenzaldehyde by using high performance liquid chromatography | |
| CN112213407B (en) | Detection method of levoornidazole related substances | |
| CN111912914B (en) | Detection method of brexpiprazole related substance | |
| CN110412164B (en) | Method for detecting related substances of mexiletine hydrochloride | |
| CN104072491A (en) | Azilsartan derivative compound and preparation method and application thereof | |
| CN114397375A (en) | Method for detecting related substances of arbidol hydrochloride intermediate | |
| CN116265937A (en) | Detection method and application of oseltamivir phosphate related impurities | |
| CN114174264A (en) | Crystal form XI of varlitinib mesylate and preparation method thereof | |
| CN117517529A (en) | Method for detecting fapirrevir and related substances thereof by HPLC and application of method | |
| CN114354788B (en) | Method for measuring related substances in Monnpiravir raw material and preparation thereof | |
| CN110850012B (en) | Detection method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride and related substances thereof | |
| CN112250657B (en) | Bicyclol dimer, preparation method and application thereof | |
| CN102285973B (en) | Paroxetine hydrochloride compound and preparation method thereof | |
| CN115598267B (en) | Analysis method of potential genotoxic impurities of glibenclamide Ji Tezhong | |
| CN112730716A (en) | Method for detecting impurities in benidipine hydrochloride bulk drug | |
| CN108373465B (en) | Dabigatran etexilate impurity and preparation and detection methods thereof | |
| CN117969686A (en) | Rayleigh Lu Geli and detection method and application of related substances thereof | |
| CN117007727A (en) | High performance liquid chromatography method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |